Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461647 | 0.88 | SIGMAR1 (0.47) | SIGMAR1MC4RPNMTACHEMEN1 | |
| Hydrochloric Acid SCHEMBL17632564 | 0.86 | SIGMAR1 (0.46) | SIGMAR1PNMTPOLBACHEMEN1 | |
| SCHEMBL13696609 | 0.85 | SIGMAR1 (0.52) | SIGMAR1MC4RPNMTLMNAPOLB | |
| SCHEMBL14211672 | 0.84 | SIGMAR1 (0.47) | SIGMAR1MC4RPNMTACHEMEN1 | |
| SCHEMBL14969763 | 0.83 | LMNA (0.49) | SIGMAR1MC4RPNMTLMNAPOLB | |
| SCHEMBL31651763 | 0.81 | SIGMAR1 (0.47) | SIGMAR1MC4RPNMTLMNAPOLB | |
| SCHEMBL14211678 | 0.81 | SIGMAR1 (0.50) | SIGMAR1MC4RPNMTLMNAPOLB | |
| SCHEMBL14211699 | 0.78 | SIGMAR1 (0.50) | SIGMAR1MC4RPNMTACHEMEN1 | |
| SCHEMBL14211675 | 0.76 | SIGMAR1 (0.43) | SIGMAR1PNMTLMNAMEN1NPC1 | |
| SCHEMBL17882258 | 0.76 | ACHE (0.42) | SIGMAR1PNMTACHEMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080086006-A1 | Process for Making Substituted Piperidines | MERCK SHARP & DOHME CORP. | 2008-04-10 | — | — | US | disclosed |
| US-20080086006-A1 | Process for Making Substituted Piperidines | MERCK SHARP & DOHME CORP. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086006-A1 | Process for Making Substituted Piperidines | ITPA, PAICS, PPIP5K2 | SIGMAR1 966/4885MC4R 4589/4885PNMT 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.